Nasdaq:JBIO

Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares

June 05, 2026 16:01 ET  | Source: Jade Biosciences SAN FRANCISCO and VANCOUVER, British Columbia, June 05, 2026 (GLOBE NEWSWIRE)…

20 hours ago

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

May 29, 2026 16:05 ET  | Source: Jade Biosciences SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE)…

1 week ago

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

October 17, 2025 16:05 ET  | Source: Jade Biosciences Presentations to highlight JADE101’s preclinical safety profile and translational framework guiding…

8 months ago